ADDING MULTIMEDIA FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic ...

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration has approved KALYDECOTM , the first medicine to treat the underlying cause of cystic fibrosis , a rare, genetic disease.

Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease.

FDA Approves KALYDECO (Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated announced recently that the U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease.